Cecilia Furlong: Great, thanks for taking the questions.
Mitch Hill: Thank you.
Drew Hykes: Thanks, Cecilia.
Operator: The next question is from Larry Biegelsen with Wells Fargo. Please go ahead.
Larry Biegelsen: Good afternoon. Thanks for taking the question. I wanted to – I have two questions, one on REVCORE, one on competition, but I was hoping you could answer Travis’s question on Q1 last year, you were up 4% sequentially consensus has you down 3% sequentially. If I missed it, I apologize, but I didn’t hear you kind of respond to that part of his question?
Drew Hykes: Yes, so Larry, it’s a little tricky here as you obviously know being six weeks into the quarter. We’ve not had a habit historically of commenting in a lot of specifics on intra quarter trends. Given some of the competitive noise, we did want at least acknowledge that we had January and February as two of among our strongest months ever. So we did want to make sure people heard that. Beyond that, I’m not sure what additional color – we’re comfortable providing at this point in the quarter. The consensus number has not been updated as you know since we put out guidance at the beginning of the year at the conference in January. Mitch, would you want to add anything beyond that on guidance and then I can follow-up on the REVCORE and the competition?
Mitch Hill: Sure, I mean, Larry, the Q1 certainly we like what we’re seeing. We’re bullish about the quarters, as Drew mentioned and that’s all I think very positive. But we’ve yet to start the month of March. It’s a big month. It has a lot of operating days in it. And so, we don’t want to get ahead of ourselves there. And I think we’re also sensitive as you can expect to this concept of kind of giving the intra quarter guidance for the business. I think we’re just trying to help people understand that we’re continuing to feel very confident in our plans 2023 and 2023 is off to a great start.
Larry Biegelsen: Okay, that’s helpful. Hi Drew, on the REVCORE and competition, so REVCORE, I’m sorry, yes, can you talk about the market opportunity, the mechanism of action and do you think it’s going to work for acute and chronic venous clots and plots and I did have 1 follow-up?
Drew Hykes: Yes, I can get started. Tom, may want to chime in clinically as well. So REVCORE, you may recall it’s a product that we designed specifically for in stent thrombosis. So lots of being a stents being implanted and many of those stents go down over time have thrombosis and clot that forms inside the stent. Today, no good solutions or certainly no purpose built solutions to address that clinical problem. And that’s exactly what we have targeted REVCORE to address the way to safely and effectively remove clot from a implanted venous stent. Tom, would you want to add anything clinically beyond that?
Tom Tu: Sure. So Larry, as you know, our customers are highly creative interventionists that will use tools that have FDA approved in any manner that they think might help their patients. So although REVCORE is purpose built to address the in stent thrombosis problem that currently has no good solutions. We think that potentially physicians will find additional uses for it in their VTE armamentarium.
Larry Biegelsen: Okay, I got it all right. So, on the competition, so obviously Penumbra is comparing Lightning FLASH to your products in their promotional material. It sounds like Drew, on this call, you’re saying you believe you can remove more clot with less blood loss and I heard that both for, I believe, DVT and PE. So I guess my question is one, is there any way to quantify this how do you quantify this, I guess? And two, the case you mentioned upfront with the new French-device, I have to believe that was Lightning FLASH. So my question is how common do you think 1000 milliliters blood loss is. Is that, that sounds like an outlier? I’m just curious. So a little more quantification of why you believe the reasons that your products are better? Thank you.
